CAN-1012

Primary objectives: 1) To evaluate the safety and tolerability of CAN1012 injection combined with toripalimab in participants with advanced solid tumors; 2) To determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of CAN1012 injection combined with toripalimab. Secondary objectives: 1) To evaluate the preliminary efficacy of CAN1012 injection combined with toripalimab in participants with advanced solid tumors; 2) To evaluate the pharmacodynamic (PD) characteristics of CAN1012 injection combined with toripalimab in participants with advanced solid tumors.

Primary objectives: 1) To evaluate the safety and tolerability of CAN1012 injection in patients with advanced solid tumors; 2) To determine the maximum tolerated dose (MTD) and/or phase II recommended dose (RP2D). Secondary objectives: 1) To evaluate the pharmacokinetic (PK) characteristics of CAN1012 injection in patients with advanced solid tumors; 2) To evaluate the preliminary efficacy of CAN1012 injection in patients with advanced solid tumors. Exploratory objectives: 1) To evaluate the pharmacodynamic (PD) characteristics of CAN1012 injection in patients with advanced solid tumors; 2) To explore the correlation between biomarkers (including CD3, CD8, PD-L1, BDCA2) and the efficacy of CAN1012 injection.